QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
NASDAQ:EQRX

EQRx Stock Forecast, Price & News

$4.20
-0.09 (-2.10%)
(As of 01/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.16
▼
$4.60
50-Day Range
N/A
52-Week Range
$3.97
▼
$11.10
Volume
881,535 shs
Average Volume
948,246 shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive EQRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.


EQRx logo

About EQRx

EQRx Inc. is a pharmaceutical company is involved in developing and delivering medicines to patients. EQRx Inc., formerly known as CM Life Sciences III, is based in NEW YORK.

Headlines

EQRx (NASDAQ:EQRX) Shares Up 2.4%
January 25, 2022 |  americanbankingnews.com
Cramer Gives His Opinion On ADT, Occidental Petroleum And More
January 25, 2022 |  msn.com
EQRx (NASDAQ:EQRX) Shares Gap Up to $4.43
January 24, 2022 |  americanbankingnews.com
EQRx (NASDAQ:EQRX) Shares Gap Down to $5.43
January 20, 2022 |  americanbankingnews.com
EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings
January 19, 2022 |  finance.yahoo.com
EQRx (NASDAQ:EQRX) Sets New 1-Year Low at $5.51
January 19, 2022 |  americanbankingnews.com
CStone-EQRx's sugemalimab improves survival of lung cancer patients in phase 3 trial
January 19, 2022 |  seekingalpha.com
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
January 19, 2022 |  finance.yahoo.com
EQRx : Phase 3 Study On Sugemalimab Shows Overall Survival Benefit In Non-small Cell Lung Cancer
January 19, 2022 |  nasdaq.com
Investors aren't buying EQRx's pitch for 'radically lower' drug prices. The CEO of the $3 billion startup tells us why she's doubling down despite a stock drop.
January 19, 2022 |  msn.com
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
January 19, 2022 |  finance.yahoo.com
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
January 19, 2022 |  finance.yahoo.com
EQRx (NASDAQ:EQRX) Shares Gap Up to $6.45
January 18, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EQRX
Previous Symbol
CUSIP
N/A
CIK
1843762
Web
iii.cmlifesciencesspac.com
Phone
212-474-6745
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.03
Quick Ratio
1.03

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
487,633,000
Free Float
N/A
Market Cap
$2.05 billion
Optionable
Optionable

Company Calendar

Today
1/27/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

1409th out of 1,419 stocks

Pharmaceutical Preparations Industry

678th out of 684 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












EQRx (NASDAQ:EQRX) Frequently Asked Questions

What is EQRx's stock symbol?

EQRx trades on the NASDAQ under the ticker symbol "EQRX."

Who are EQRx's major shareholders?

EQRx's stock is owned by a number of retail and institutional investors. Top institutional investors include Tybourne Capital Management HK Ltd. (0.47%), Belvedere Trading LLC (0.00%) and Brown Advisory Inc. (0.00%).

Which major investors are buying EQRx stock?

EQRX stock was acquired by a variety of institutional investors in the last quarter, including Tybourne Capital Management HK Ltd., Belvedere Trading LLC, and Brown Advisory Inc..

How do I buy shares of EQRx?

Shares of EQRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EQRx's stock price today?

One share of EQRX stock can currently be purchased for approximately $4.20.

How much money does EQRx make?

EQRx has a market capitalization of $2.05 billion.

What is EQRx's official website?

The official website for EQRx is iii.cmlifesciencesspac.com.

Where are EQRx's headquarters?

EQRx is headquartered at 667 MADISON AVENUE, NEW YORK NY, 10065.

How can I contact EQRx?

EQRx's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The company can be reached via phone at 212-474-6745.


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.